Ozempic, originally a diabetes medication, has gained popularity as a weight-loss solution, leading Novo Nordisk to pay a record 4.9 million francs to healthcare professionals in 2023. The drug generated the highest costs among diabetes medications, totaling 81.2 million francs, with a significant increase in sales. Recent studies suggest its effectiveness in overweight children, prompting financial support for medical professionals involved in its promotion.